Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 21, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 ordinary shares of 25 pence each.
- Purchase Price: 1,484.19 pence per share.
- Treasury Holdings Post-Transaction: 174,756,678 shares.
- Shares in Issue (excluding Treasury): 5,807,832,686 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 500,000 shares on June 21, 2006, which are now held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase based on the disclosed price of 1,484.19 pence per share.
- Confirm the updated total share capital structure, noting the increase in Treasury shares to 174,756,678.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authority granted.